Antibody Therapeutics最新文献

{"title":"A VHH single-domain platform enabling discovery and development of monospecific antibodies and modular neutralizing bispecifics against SARS-CoV-2 variants","authors":"Marisa L Yang, Tom Z. Yuan, Kara Y Chan, Lin Ding, Zhen Han, Hector Franco, Carson Holliday, Shruthi Kannan, E. Davidson, B. Doranz, K. Chandran, E. H. Miller, Jessica A. Plante, Scott C Weaver, Eunice Cho, Shweta Kailasan, Lukas Marsalek, Hoa Giang, Y. Abdiche, Aaron Sato","doi":"10.1093/abt/tbae009","DOIUrl":"https://doi.org/10.1093/abt/tbae009","url":null,"abstract":"\u0000 \u0000 \u0000 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, escape coronavirus disease 2019 therapeutics and vaccines, and jeopardize public health.\u0000 \u0000 \u0000 \u0000 To combat SARS-CoV-2 antigenic escape, we developed a rapid, high-throughput pipeline to discover monospecific VHH antibodies and iteratively develop VHH-Fc-VHH bispecifics capable of neutralizing emerging SARS-CoV-2 variants.\u0000 \u0000 \u0000 \u0000 By panning VHH single-domain phage libraries against ancestral or Beta spike proteins, we discovered high-affinity VHH antibodies with unique target epitopes. Combining two VHHs into a tetravalent bispecific construct conferred broad neutralization activity against multiple variants and was more resistant to antigenic escape than the monospecific antibody alone. Following the rise of the Omicron variant, a VHH in the original bispecific construct was replaced with another VHH discovered against Omicron BA.1 receptor binding domain—the resulting bispecific exhibited neutralization against both BA.1 and BA.5 sublineage variants.\u0000 \u0000 \u0000 \u0000 A heavy chain-only tetravalent VHH-Fc-VHH bispecific platform derived from humanized synthetic libraries held a myriad of unique advantages: 1) synthetic preconstructed libraries minimized risk of liabilities and maximized discovery speed, 2) VHH scaffolds allowed for a modular “plug-and-play” format that could be rapidly iterated upon as variants of concern arose, 3) natural dimerization of single VHH-Fc-VHH polypeptides allowed for straightforward bispecific production and purification methods, and 4) multivalent approaches enhanced avidity boosting effects and neutralization potency, and conferred more robust resistance to antigenic escape than monovalent approaches against specific variants. This iterative platform of rapid VHH discovery combined with modular bispecific design holds promise for long-term viral control efforts.\u0000","PeriodicalId":36655,"journal":{"name":"Antibody Therapeutics","volume":"95 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141017619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structure and function of therapeutic antibodies approved by the US FDA in 2023","authors":"William R Strohl","doi":"10.1093/abt/tbae007","DOIUrl":"https://doi.org/10.1093/abt/tbae007","url":null,"abstract":"\u0000 In calendar year 2023, the United States Food and Drug Administration (US FDA) approved a total of 55 new molecular entities (NMEs), of which 12 were in the class of therapeutic antibodies. Besides antibody protein drugs, the US FDA also approved another five non-antibody protein drugs, making the broader class of protein drugs about 31% of the total approved drugs. Amongst the 12 therapeutic antibodies approved by the US FDA, eight were relatively standard IgG formats, three were bivalent, bispecific antibodies, and one was a trivalent, bispecific antibody. In 2023, no new antibody-drug conjugates, immunocytokines, or chimeric antigen receptor T (CAR-T) cells were approved. Of the approved antibodies, two targeted programmed cell death receptor (PD)-1 for orphan indications, two targeted CD20 for diffuse large B cell lymphoma (DLBCL), two different targets (B-cell maturation antigen [BCMA] and G-coupled protein receptor class C, group 5, member D [GPRC5D]) for treatment of multiple myeloma (MM), and one each that targeted amyloid-β protofibrils for Alzheimer’s disease, neonatal Fc receptor (FcRn) alpha-chain for myasthenia gravis, complement factor C5 for CD55 deficiency with Hyper-activation of complement, Angiopathic thrombosis, and severe Protein-Losing Enteropathy (CHAPLE) disease, interleukin (IL)-23p19 for severely active ulcerative colitis, IL-17A-F for plaque psoriasis, and respiratory syncytial virus (RSV)-F protein for season-long RSV prophylaxis in infants.","PeriodicalId":36655,"journal":{"name":"Antibody Therapeutics","volume":"74 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140229908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a novel humanized anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential","authors":"Xiaolei Liu, Jianzhong Han, Qian Wang, Peng Wang, Li Li, Kehe Du, Fengchao Jiang, Pei Zhang, Hongjun Liu, Jian Huang","doi":"10.1093/abt/tbae006","DOIUrl":"https://doi.org/10.1093/abt/tbae006","url":null,"abstract":"Abstract Thymic stromal lymphopoietin (TSLP) is a member of the IL-2 cytokine family and has been widely recognized as a master regulator of type 2 inflammatory responses at barrier surfaces. Recent studies found dysregulation of the TSLP–TSLP receptor (TSLPR) pathway is associated with the pathogenesis of not only allergic diseases but also a wide variety of cancers including both solid tumors and hematological tumors. Thus, the blockade of TSLP represents an attractive therapeutic strategy for allergic diseases and cancer. In this study, we report the development of a novel humanized anti-TSLP monoclonal antibody (mAb) HZ-1127. Binding affinity, specificity, and ability of HZ-1127 in inhibiting TSLP were tested. HZ-1127 selectively binds to the TSLP cytokine with high affinity and specificity. Furthermore, HZ-1127 dramatically inhibits TSLP-dependent STAT5 activation and is more potent than Tezepelumab, which is an FDA-approved humanized mAb against TSLP for severe asthma treatment in inhibiting TSLP-induced CCL17 and CCL22 chemokines secretion in human peripheral blood mononuclear cells. Our pre-clinical study demonstrates that HZ-1127 may serve as a potential therapeutic agent for allergic diseases and cancer.","PeriodicalId":36655,"journal":{"name":"Antibody Therapeutics","volume":"55 9","pages":"123 - 130"},"PeriodicalIF":0.0,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140425694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate","authors":"Xiaojie Ma, Mingkai Wang, Tianlei Ying, Yan-ling Wu","doi":"10.1093/abt/tbae005","DOIUrl":"https://doi.org/10.1093/abt/tbae005","url":null,"abstract":"Abstract In recent years, substantial therapeutic efficacy of antibody-drug conjugates (ADCs) has been validated through approvals of 16 ADCs for the treatment of malignant tumors. However, realization of the maximum clinical use of ADCs requires surmounting extant challenges, mainly the limitations in tumor penetration capabilities when targeting solid tumors. To resolve the hurdle of suboptimal tumor penetration, miniaturized antibody fragments with engineered formats have been harnessed for ADC assembly. By virtue of their reduced molecular sizes, antibody fragment-drug conjugates hold considerable promise for efficacious delivery of cytotoxic agents, thus conferring superior therapeutic outcomes. This review will focus on current advancements in novel ADC development utilizing smaller antibody formats from ~6 to 80 kDa, with particular emphasis on single-domain antibodies, which have been widely applied in novel ADC design. Additionally, strategies to optimize clinical translation are discussed, including half-life extension, acceleration of internalization, and reduction of immunogenic potential.","PeriodicalId":36655,"journal":{"name":"Antibody Therapeutics","volume":"310 1","pages":"114 - 122"},"PeriodicalIF":0.0,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140453684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Bringing cell therapy to tumors: considerations for optimal CAR binder design","authors":"","doi":"10.1093/abt/tbae003","DOIUrl":"https://doi.org/10.1093/abt/tbae003","url":null,"abstract":"","PeriodicalId":36655,"journal":{"name":"Antibody Therapeutics","volume":"76 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139963975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding the pharmacokinetic journey of fc-fusion protein, rhIL-7-hyFc, using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA","authors":"Anhye Kim, Min-Seok Oh, Gwan-Ho Lee, Seongeun Song, Mi-sun Byun, Donghoon Choi, Byung-Yong Yu, Howard Lee","doi":"10.1093/abt/tbae004","DOIUrl":"https://doi.org/10.1093/abt/tbae004","url":null,"abstract":"\u0000 \u0000 \u0000 Antibody-based therapeutics (ABTs) including monoclonal/polyclonal antibodies and Fc-fusion proteins are increasingly used in disease treatment, driving the global market growth. Understanding the pharmacokinetic (PK) properties of ABTs is crucial for their clinical effectiveness. This study investigated the PK profile and tissue distribution of efineptakin alfa, a long-acting recombinant human interleukin-7 (rhIL-7-hyFc), using enzyme-linked immunosorbent assay (ELISA) and accelerator mass spectrometry (AMS).\u0000 \u0000 \u0000 \u0000 Total 4 rats were injected intramuscularly with 1 mg/kg of rhIL-7-hyFc containing 14C-rhIL-7-hyFc, prepared via reductive methylation. Serum total radioactivity (TRA) and serum rhIL-7-hyFc concentrations were quantified using AMS and ELISA, respectively. TRA concentrations in organs were determined by AMS.\u0000 \u0000 \u0000 \u0000 Serum TRA peaked at 10 hours with a terminal half-life of 40 hours. rhIL-7-hyFc exhibited a mean peak concentration at around 17 hours and a rapid elimination with a half-life of 12.3 hours. Peak concentration and area under the curve of TRA were higher than those of rhIL-7-hyFc. Tissue distribution analysis showed elevated TRA concentrations in lymph nodes, kidneys, and spleen, indicating rhIL-7-hyFc’s affinity for these organs. The study also simulated the positions of 14C labeling in rhIL-7-hyFc, identifying specific residues in the fragment of rhIL-7 portion, and provided the explanation of distinct analytes targeted by each method.\u0000 \u0000 \u0000 \u0000 Combining ELISA and AMS provided advantages by offering sensitivity and specificity for quantification, as well as enabling the identification of analyte forms. The integrated use of ELISA and AMS offer valuable insights for the development and optimization of ABT.\u0000","PeriodicalId":36655,"journal":{"name":"Antibody Therapeutics","volume":"4 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139800525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding the pharmacokinetic journey of fc-fusion protein, rhIL-7-hyFc, using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA","authors":"Anhye Kim, Min-Seok Oh, Gwan-Ho Lee, Seongeun Song, Mi-sun Byun, Donghoon Choi, Byung-Yong Yu, Howard Lee","doi":"10.1093/abt/tbae004","DOIUrl":"https://doi.org/10.1093/abt/tbae004","url":null,"abstract":"\u0000 \u0000 \u0000 Antibody-based therapeutics (ABTs) including monoclonal/polyclonal antibodies and Fc-fusion proteins are increasingly used in disease treatment, driving the global market growth. Understanding the pharmacokinetic (PK) properties of ABTs is crucial for their clinical effectiveness. This study investigated the PK profile and tissue distribution of efineptakin alfa, a long-acting recombinant human interleukin-7 (rhIL-7-hyFc), using enzyme-linked immunosorbent assay (ELISA) and accelerator mass spectrometry (AMS).\u0000 \u0000 \u0000 \u0000 Total 4 rats were injected intramuscularly with 1 mg/kg of rhIL-7-hyFc containing 14C-rhIL-7-hyFc, prepared via reductive methylation. Serum total radioactivity (TRA) and serum rhIL-7-hyFc concentrations were quantified using AMS and ELISA, respectively. TRA concentrations in organs were determined by AMS.\u0000 \u0000 \u0000 \u0000 Serum TRA peaked at 10 hours with a terminal half-life of 40 hours. rhIL-7-hyFc exhibited a mean peak concentration at around 17 hours and a rapid elimination with a half-life of 12.3 hours. Peak concentration and area under the curve of TRA were higher than those of rhIL-7-hyFc. Tissue distribution analysis showed elevated TRA concentrations in lymph nodes, kidneys, and spleen, indicating rhIL-7-hyFc’s affinity for these organs. The study also simulated the positions of 14C labeling in rhIL-7-hyFc, identifying specific residues in the fragment of rhIL-7 portion, and provided the explanation of distinct analytes targeted by each method.\u0000 \u0000 \u0000 \u0000 Combining ELISA and AMS provided advantages by offering sensitivity and specificity for quantification, as well as enabling the identification of analyte forms. The integrated use of ELISA and AMS offer valuable insights for the development and optimization of ABT.\u0000","PeriodicalId":36655,"journal":{"name":"Antibody Therapeutics","volume":"61 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139860662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Further Accelerating Biologics Development from DNA to IND: The Journey from COVID-19 to Non-COVID-19 Programs","authors":"Kee Wee Tan, Pengfei Ji, Hang Zhou, Sam Zhang, Weichang Zhou","doi":"10.1093/abt/tbae001","DOIUrl":"https://doi.org/10.1093/abt/tbae001","url":null,"abstract":"\u0000 The COVID-19 pandemic has spurred adoption of revolutionary initiatives by regulatory agencies and pharmaceutical industry worldwide to deliver therapeutic COVID-19 antibodies to patients at unprecedented speed. Among these, timeline of Chemistry, Manufacturing, and Control (CMC), which involves process development and manufacturing activities critical for the assurance of product quality and consistency before first-in-human clinical trials, was greatly reduced from typically 12-15 months (using clonal materials) to approximately 3 months (using non-clonal materials) in multiple cases. In this perspective, we briefly review the acceleration approaches published for therapeutic COVID-19 antibodies and subsequently discuss the applicability of these approaches to achieve investigational new drug (IND) timelines of ≤10 months in over 60 COVID-19 and non-COVID-19 programs performed at WuXi Biologics. We are of the view that, with demonstrated product quality and consistency, innovative approaches used for COVID-19 can be widely applied in all disease areas for greater speed to clinic.","PeriodicalId":36655,"journal":{"name":"Antibody Therapeutics","volume":"13 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139600199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of fc glycosylation on the activity of WNT mimetic agonistic antibodies","authors":"Hui Chen, Sung-Jin Lee, Brian Ouyang, Nicholas Suen, Jay Ye, Cheng-yu Lu, Yang Li","doi":"10.1093/abt/tbae002","DOIUrl":"https://doi.org/10.1093/abt/tbae002","url":null,"abstract":"\u0000 Monoclonal antibodies have been explored in a broad range of applications including receptor agonism. Given the importance of receptor conformation in signaling, the agonistic activity of antibodies that engage these receptors are influenced by many parameters. Tetravalent bispecific antibodies that target the FZD and LRP receptors and subsequently activate WNT signaling have been constructed. Because WNT activation stimulates stem cell proliferation and tissue regeneration, immune effector functions should be eliminated from therapeutic antibodies targeting this pathway. Here, we report an unexpected effect of Fc glycosylation on the agonistic activity of WNT mimetic antibodies. Our findings underscore the importance of antibody format, geometry, and epitope in agonistic antibody design, and highlight the need to establish appropriate early discovery screening strategies to identify hits for further optimization.","PeriodicalId":36655,"journal":{"name":"Antibody Therapeutics","volume":"124 48","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139615189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GB12–09, a bispecific antibody targeting IL4Rα and IL31Rα for atopic dermatitis therapy","authors":"Feiyan Deng, Yuxin Qiu, Xiangling Zhang, Nining Guo, Junhong Hu, Wenjie Yang, Wei Shang, Bicheng Liu, Suofu Qin","doi":"10.1093/abt/tbad032","DOIUrl":"https://doi.org/10.1093/abt/tbad032","url":null,"abstract":"\u0000 \u0000 \u0000 Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by dysregulated immune responses. The key mediators of AD pathogenesis are T helper 2 (TH2) cells and TH2 cytokines. Targeting interleukin 4 (IL4), IL13, or IL31 has become a pivotal focus in both research and clinical treatments for AD. However, the need remains pressing for the development of a more effective and safer therapy, as the current approaches often yield low response rates and adverse effects.\u0000 \u0000 \u0000 \u0000 In response to this challenge, we have engineered an IgG-scFv (Immunoglobulin G—single-chain Fragment variable) format bispecific antibody designed to concurrently target IL4R and IL31R. Our innovative design involved sequence optimization of VL-VH and the introduction of disulfide bond (VH44-VL100) within the IL31Rα antibody scFv region to stabilize the scFv structure.\u0000 \u0000 \u0000 \u0000 Our bispecific antibody efficiently inhibited the IL4/IL13/IL31 signaling pathways in vitro and reduced serum Immunoglobulin E (IgE) and IL31 levels in vivo. Consequently, this intervention led to improved inflammation profiles and notable amelioration of AD symptoms.\u0000 \u0000 \u0000 \u0000 This research highlighted a novel approach to AD therapy by employing bispecific antibody targeting IL4Rα and IL31Rα with potent efficacy.\u0000","PeriodicalId":36655,"journal":{"name":"Antibody Therapeutics","volume":"23 15","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139382968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}